C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.75 USD 3.6%
Market Cap: 77.1m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Accounts Receivables Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Accounts Receivables
$9.6m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accounts Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Accounts Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%

See Also

What is CASI Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
9.6m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Accounts Receivables amounts to 9.6m USD.

What is CASI Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
28%

Over the last year, the Accounts Receivables growth was -27%. The average annual Accounts Receivables growth rates for CASI Pharmaceuticals Inc have been 28% over the past three years .

Back to Top